Introduction:

Persons with gender dysphoria feel incongruity between the sex they are born with and the one they feel they belong to, therefore they need to adapt their body to the latter, and one of the pillars in achieving that purpose is the use of cross hormonal treatment.

Objective:

To identify the therapeutic schemes most used in self-medication and specialized management, and their complications in patients with gender dysphoria.

Methods:

Seventy eight medical records were reviewed. Seventy six of them corresponded to male-female transsexuals, assisted in the 2012-2017 period at the National Consultation of Comprehensive Care to Transgender Persons. The study team recovered information related to the therapeutic schemes used, both during self-medication and during the endocrinological management, as well as complications. Frequency distributions of the qualitative variables, mean and standard deviation of the quantitative variables were obtained for data analysis.

Results:

The frequency of patients who self-administered hormones before beginning specialized care was 82.9%. The most commonly medication used in self-medication was cypress (cyproterone acetate 2 mg / ethinylestradiol 50 µg) in 90.5% of cases. Out of the treatments indicated by the endocrinologist at the beginning of the care; 50.0% were given cypress plus androcur (50 mg cyproterone acetate) of 1 to 2 tablets each, while 39.5% conjugated estrogens associated with androcur, also 1 to 2 tablets of each of these medications. Regarding the frequency of complications as a result of hormonal treatment, 40.7% of the cases had elevated prolactin levels at some time, and triglyceride levels increased to 26.3% after the start of therapy.

Conclusions:

Most patients who come for the first time, are self-medicated. The most used medications are cipresta and androcur. The most frequent complication is hyperprolactinemia as a consequence of treatment.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )